Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Rhabdomyosarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (572
)
Soft Tissue Sarcoma (126
)
Osteosarcoma (51
)
Liposarcoma (43
)
Ewing Sarcoma (40
)
Fibrosarcoma (33
)
Leiomyosarcoma (30
)
Uterine Corpus Leiomyosarcoma (20
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Spindle Cell Sarcoma (8
)
Sarcoma (572
)
Soft Tissue Sarcoma (126
)
Osteosarcoma (51
)
Liposarcoma (43
)
Ewing Sarcoma (40
)
Fibrosarcoma (33
)
Leiomyosarcoma (30
)
Uterine Corpus Leiomyosarcoma (20
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (12
)
Spindle Cell Sarcoma (8
)
›
Associations
(27)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
dactinomycin
Sensitive: A1 - Approval
dactinomycin
Sensitive
:
A1
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
IE
Sensitive: A2 - Guideline
IE
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
trabectedin
Sensitive: A2 - Guideline
trabectedin
Sensitive
:
A2
trabectedin
Sensitive: A2 - Guideline
trabectedin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
ADX-2191
Sensitive: A2 - Guideline
ADX-2191
Sensitive
:
A2
ADX-2191
Sensitive: A2 - Guideline
ADX-2191
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
vinorelbine
Sensitive: A2 - Guideline
vinorelbine
Sensitive
:
A2
vinorelbine
Sensitive: A2 - Guideline
vinorelbine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
topotecan
Sensitive: A2 - Guideline
topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
SA033
Sensitive: A2 - Guideline
SA033
Sensitive
:
A2
SA033
Sensitive: A2 - Guideline
SA033
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
temozolomide + irinotecan + vincristine
Sensitive
:
A2
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
temozolomide + irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
cyclophosphamide + vinorelbine tartrate
Sensitive: A2 - Guideline
cyclophosphamide + vinorelbine tartrate
Sensitive
:
A2
cyclophosphamide + vinorelbine tartrate
Sensitive: A2 - Guideline
cyclophosphamide + vinorelbine tartrate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
vincristine + dactinomycin
Sensitive: A2 - Guideline
vincristine + dactinomycin
Sensitive
:
A2
vincristine + dactinomycin
Sensitive: A2 - Guideline
vincristine + dactinomycin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
irinotecan + vincristine
Sensitive: A2 - Guideline
irinotecan + vincristine
Sensitive
:
A2
irinotecan + vincristine
Sensitive: A2 - Guideline
irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive
:
A2
PD-L1 expression
Rhabdomyosarcoma
PD-L1 expression
Rhabdomyosarcoma
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
anlotinib
Resistant: C4 – Case Studies
anlotinib
Resistant
:
C4
anlotinib
Resistant: C4 – Case Studies
anlotinib
Resistant
:
C4
PD-L1 expression
Rhabdomyosarcoma
PD-L1 expression
Rhabdomyosarcoma
pazopanib
Resistant: C4 – Case Studies
pazopanib
Resistant
:
C4
pazopanib
Resistant: C4 – Case Studies
pazopanib
Resistant
:
C4
EWSR1-TFCP2 fusion
Rhabdomyosarcoma
EWSR1-TFCP2 fusion
Rhabdomyosarcoma
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
HRAS mutation
Rhabdomyosarcoma
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive: D – Preclinical
tipifarnib
Sensitive
:
D
tipifarnib
Sensitive: D – Preclinical
tipifarnib
Sensitive
:
D
KDM1A overexpression
Rhabdomyosarcoma
KDM1A overexpression
Rhabdomyosarcoma
SP2577
Sensitive: D – Preclinical
SP2577
Sensitive
:
D
SP2577
Sensitive: D – Preclinical
SP2577
Sensitive
:
D
PAX3-FOXO1 fusion
Rhabdomyosarcoma
PAX3-FOXO1 fusion
Rhabdomyosarcoma
SNDX-275
Sensitive: D – Preclinical
SNDX-275
Sensitive
:
D
SNDX-275
Sensitive: D – Preclinical
SNDX-275
Sensitive
:
D
HER-2 expression
Rhabdomyosarcoma
HER-2 expression
Rhabdomyosarcoma
T-lymphocyte cell therapy
Sensitive: D – Preclinical
T-lymphocyte cell therapy
Sensitive
:
D
T-lymphocyte cell therapy
Sensitive: D – Preclinical
T-lymphocyte cell therapy
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
